NHS funding for use of Bristol-Myers Squibb’s Opdivo as an adjuvant treatment for resected stage III and IV melanoma is being blocked by the National Institute for Health and Care Excellence. More: NICE rejects Opdivo for preventing melanoma recurrence Source:
read moreA new NHS campaign is striving to clamp down on the millions of pounds worth of prescriptions incorrectly claimed for free each year. More: NHS moves to clamp down on incorrect/fraudulent prescriptions Source: News
read moreWithout additional funding, the world won’t see new “highly efficacious” vaccines against HIV, tuberculosis and malaria, according to a new study. More: Needed vaccines against HIV, malaria and tuberculosis unlikely to launch at current funding levels: study Source: fierce
read moreCoca-Cola was said to be among several players eyeing GlaxoSmithKline’s Indian consumer products business, including its storied drinks brand Horlicks, and now the beverages giant is ready to jump into the mix with a multibillion-dollar offer. More: Bidding war? Coca-Cola
read moreLast week, GlaxoSmithKline used the tried-and-true technique of releasing bad news late on a Friday, when most people have checked out for the weekend. The disappointment? Its asthma drug Nucala, key to its respiratory strategy, got a thumbs-down from the
read moreTakeda’s Shire buyout has driven a wedge between the deal’s mastermind, CEO Christophe Weber, and the founding Takeda family, as a senior member of the family publicly voiced his opposition to the $62 billion deal, calling it a potential disaster.
read more© 1994 - 2026 B.M. Pharmaceuticals